An mRNA allergy vaccine reportedly reduced airway inflammation in mice

A post describes researchers testing an mRNA-lipid nanoparticle vaccine designed to retrain mice’s immune responses to allergens. It reports less airway inflammation, mucus and hyperreactivity, a shift away from allergy-promoting Th2/Th17 responses, and more IgG antibodies without a rise in IgE. The post says the approach also worked in mice with existing allergies.